ADC2336

ADC2336 is an investigational antibody-drug conjugate (ADC) developed for oncology indications. It is designed using the MuSC platform, which enables the combination of two drugs with different mechanisms of action to achieve synergistic effects in disrupting cancer cell organelles. The specific targets, payloads, and linker technology for ADC2336 have not been publicly disclosed as of April 2025. The drug is being evaluated in preclinical or early clinical studies for its antitumor activity and safety profile. Antibody-drug conjugates like ADC2336 typically function by binding to a tumor-associated antigen on cancer cells via their antibody component, followed by internalization and release of a cytotoxic payload that induces cell death.